Digital On AI and computational support of biochemistry, with Alan R... Dr Alan Roth, CEO of Oxford Drug Design, discusses the use of AI to accelerate discovery of new treatments.
News Lilly unveils employer scheme for weight-loss drug Zepbound Eli Lilly has added another channel to its selling options for obesity therapy Zepbound in the US, launching a programme directed at employers.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
